Jeffrey Frank, MD
Neurology · Louisville, KYNPI 1073664470
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $138,005 of the $181,002 with a category attached, or 76.2%. It is spread thinly across 35 manufacturers, the largest accounting for just 23.0%. Reporting peaked in 2021 at $49,343 and has fallen 72.1% since, to $13,780 in 2025. Among neurology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 962 payments — averaging $188.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$42K
- Amgen$36K
- Biohaven Pharmaceuticals, Inc.$32K
- AbbVie$31K
- Teva Pharmaceuticals USA, Inc.$20K
- Biohaven Pharmaceutical Holding Company Ltd.$7K
- plus $12K from 29 others
What the payments were for
- Consulting fees$22,18812%
- Speaking & faculty fees$138,00576%
- Travel & lodging$3,7922%
- Food & beverage$17,0179%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 76 | $41,655 |
| Amgen | 99 | $36,304 |
| Biohaven Pharmaceuticals, Inc. | 75 | $31,901 |
| AbbVie(2 entities) | 217 | $31,181 |
| Teva Pharmaceuticals USA, Inc. | 55 | $20,274 |
| Biohaven Pharmaceutical Holding Company Ltd. | 14 | $7,227 |
| Impel Pharmaceuticals Inc. | 15 | $6,871 |
| Pfizer | 78 | $977 |
| Sunovion Pharmaceuticals Inc. | 66 | $849 |
| Biogen | 46 | $751 |
| UCB, Inc. | 37 | $567 |
| Novartis | 45 | $548 |
| Genentech USA, Inc. | 14 | $311 |
| Supernus Pharmaceuticals, Inc. | 39 | $201 |
| Acorda Therapeutics, Inc | 14 | $199 |
| Lilly USA, LLC | 12 | $182 |
| Sanofi | 11 | $173 |
| Avanir Pharmaceuticals, Inc. | 7 | $103 |
| Amneal Pharmaceuticals LLC | 5 | $96 |
| AstraZeneca(2 entities) | 5 | $79 |
| Merz Pharmaceuticals, LLC | 2 | $77 |
| EMD Serono, Inc. | 5 | $71 |
| Mallinckrodt Enterprises LLC | 4 | $60 |
| Collegium Pharmaceutical, Inc. | 1 | $52 |
| MDD US Operations, LLC | 3 | $46 |
| Mallinckrodt Hospital Products Inc. | 2 | $41 |
| Neurocrine Biosciences, Inc. | 3 | $40 |
| Acadia Pharmaceuticals Inc | 2 | $30 |
| Merz North America, Inc. | 2 | $29 |
| Jazz Pharmaceuticals Inc. | 2 | $28 |
| Zyla Life Sciences, Inc. | 2 | $24 |
| Johnson & Johnson | 1 | $18 |
| Assertio Therapeutics, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Endo Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$181,002 in reported general payments places this provider in the 95th percentile of 210 neurology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 202 | $187,708 |
| UbrelvyUbrogepant | 144 | $184,540 |
| QuliptaAtogepant | 142 | $173,605 |
| Nurtec OdtRimegepant Sulfate | 119 | $153,943 |
| Emgality PenGalcanezumab-Gnlm | 95 | $82,511 |
| KeppraLevetiracetam | 23 | $39,311 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 28 | $27,164 |
| TopamaxTopiramate | 15 | $18,495 |
| Zonisamide | 231 | $7,734 |
| Carbamazepine ErCarbamazepine | 36 | $7,135 |
| FetzimaLevomilnacipran Hcl | 12 | $6,087 |
| ZonisadeZonisamide | 11 | $5,245 |
| Oxcarbazepine | 66 | $4,884 |
| Gabapentin | 285 | $4,856 |
| Duloxetine Hcl | 233 | $4,162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta, Fetzima | $31,181 | $364,232298 claims |
| PfizerNurtec Odt, Dilantin | $977 | $157,715136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 210 neurology providers in Kentucky.
Other neurology in Louisville
- Brian PlatoLouisville$232K
- Kristi NordLouisville$217K
- Angela HardwickLouisville$187K
- Peter HederaLouisville$185K
- Mohammad AlsorogiLouisville$111K
- Tad SeifertLouisville$99K
- Michael SweeneyLouisville$71K
- Michael SowellLouisville$60K
- David RobertsonLouisville$58K
- Jenny FengLouisville$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.